|
||||||||||||||||
|
||||||||||||||||
| HUM-MOLGEN -> Events | Search | Write an announcement | ||||||||||||||||
Meetings and Conferences by date |
||||||||||||||||
| October, 04 2026 |
your calendar for events in
genetics, biotechnology and medicine |
|||||||||||||||
| October 2026 | 06-08 October 2026 Cancer Research: 5th edition EACR Cancer Metabolism |
The European Association for Cancer Research (EACR), Bilbao, Spain | ||||||||||||||
| 2026-10-06 Cancer Research: Oncology innovation is accelerating across therapeutic modalities, precision medicine, biomarkers and artificial intelligence. But as scientific possibilities expand, the growing challenge for sponsor Oncology Drug Development in 2026: From Scientific Innovation to Global Execution (Broadcast 2) |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-08 Others: Plasma fractionators face increasing pressure to improve process efficiency, product consistency and manufacturing resilience while operating in regulated, high-throughput environments. This webinar w Advancing Plasma Protein Purification with Scalable Chromatography Strategies |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-09 Microbiology / Virology: Early-phase clinical development is becoming increasingly complex, requiring sponsors to generate robust proof-of-concept data while navigating evolving study designs, diverse patient populations and Accelerating Proof-of-Concept for Complex Early-Phase Studies |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-13 Microbiology / Virology: Artificial intelligence (AI) is creating new opportunities across clinical development, from improving trial planning and execution to generating faster, more meaningful insights. As organizations con The Practical Reality of AI in Clinical Development: Governing AI for Trust, Impact and Operational Readiness |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-13 Others: As AAV-based gene therapy programs move from late-stage clinical development toward commercialization, Chemistry, Manufacturing and Controls (CMC) execution often becomes a key determinant of launch r From Platform Knowledge to Commercial Readiness: Accelerating and De-risking your AAV Therapy’s Path to Patients |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-14 Microbiology / Virology: Using patient-centric trial design and biomarker insights to support confident development decisions Generating meaningful clinical insights as early as possible is a growing priority in neurodegenera Strategic approaches for early clinical trials in neurodegenerative diseases |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-15 Others: In dermatology clinical trials, seeing change and proving clinically meaningful change are not the same thing. Disease can fluctuate between visits, severity can vary across body regions and patients Beyond the Surface: Navigating Endpoint Complexity & Safety in Dermatology Clinical Trials |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 15/10/2026 to 17/10/2026 Others: 23rd Continuing Professional Development (CPD) Series Diabetes Asia 2026 Conference (DAC 2026) |
National Diabetes Institute, voco Kuching by IHG, Kuching, Sarawak, Malaysia | |||||||||||||||
| 2026-10-20 Others: The latest innovations in cell bank manufacturing can help accelerate biologic therapeutics program while reducing risk and simplifying overall strategy. As industry expectations continue to evolve, e Reduce Cell Bank Manufacturing Risk and Accelerate Characterization |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-21 Microbiology / Virology: Neurodegenerative clinical trials present unique challenges that extend beyond scientific and operational complexity. Disease progression, caregiver responsibilities, travel burden, complex assessment Beyond the Protocol: Advancing Patient- and Caregiver-Centered Approaches in Neurodegenerative Clinical Trials |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-21 Others: No two clinical trials are the same, and therefore patient support can't be one-size-fits-all. Some patient populations, whether facing a rare disease, a difficult oncology diagnosis or significant tr Improve Clinical Trial Retention with Patient Population Support |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-22 Microbiology / Virology: Psychedelic clinical trials present unique challenges that can make successful execution fundamentally different from small molecules. The psychedelic experience, blinding, psychotherapy assistance an Executing Successful Psychedelic Studies from Protocol to Patient |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-22 Others: Finding the right participants remains one of the biggest challenges in clinical research. Precision recruitment offers a more targeted, data-informed approach, helping researchers understand who may Accelerate Participant Identification with Precision Recruitment |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-22 Others: As pet parents increasingly seek proactive solutions to support their pets' quality of life and longevity, brands are under pressure to deliver effective, clinically substantiated pet health products Formulate Pet Health Products to Improve Aging, Mobility and Immunity |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-23 Microbiology / Virology: Cardiovascular outcomes trials (CVOTs) are among the most complex and resource-intensive studies in drug development, where operational execution can significantly affect timelines, capital efficiency Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-26 Others: Bispecific antibodies have emerged as a rapidly growing biologic modality that can engage two distinct biological targets within a single molecule. Their unique mechanisms of action have created new o Manufacturing Bispecific Antibodies: Development & Scale-Up |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-27 Biotechnology: Medical information teams face a critical inflection point as they move toward first product approval, launch or rapid commercial growth. A PDUFA date or the release of new clinical data can quickly e The Last Human Mile in Medical Information: Scaling Biotech Launch Support |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-28 Microbiology / Virology: Biopharmaceutical teams are increasingly looking to AI to improve process development and optimization. However, the biggest constraint is often not the model; it’s the data. If experiments are run at High-Throughput Antibody Workflows for AI-Enabled Process Optimization |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-28 Others: Pharmacovigilance intake processes must keep pace with the growing volume and variety of incoming data. Potential adverse events and product quality complaints can arrive through emails, lab reports, Improve Pharmacovigilance Quality with AI-Enabled Case Intake |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-29 Others: The future of cell and gene therapy will be shaped not only by clinical breakthroughs but also by the industry's ability to connect patients, providers, payers and support services in an increasingly Scale Cell & Gene Therapy Access for Stronger Launch Readiness (Broadcast 1) |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-29 Others: Weight-loss medications work only while patients keep taking them. The real goal is staying on medication long enough to achieve meaningful, functional weight loss and sustain it. This webinar explore Beyond Biometrics: Connecting Behavioral Profiles to Achieve the Right Kind of Weight Loss |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-29 Pharmacogenetics / Pharmacogenomics: From Robust Clone Outgrowth to GMP-Ready Cell Banks Ensuring the clinical reliability of iPSC-derived products begins with genetically stable and well-characterized starting materials. This webinar pr Optimizing Single-Cell Cloning Workflows for iPSC Manufacturing |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-30 Others: With peptide conjugate therapies achieving blockbuster sales and around 300 peptide-drug conjugates having entered clinical development, interest is expanding across new conjugate types and therapeuti Accelerate Peptide Synthesis Timelines for Complex Conjugates |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-10-30 Others: The future of cell and gene therapy will be shaped not only by clinical breakthroughs but also by the industry's ability to connect patients, providers, payers and support services in an increasingly Scale Cell & Gene Therapy Access for Stronger Launch Readiness (Broadcast 2) |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| November 2026 | 2026-11-02 Others: Clinical trials succeed or fail at the intersection of two communities: patients who volunteer their time and participation and sites that dedicate resources, expertise and empathy to guide them throu Build Patient-Site Trust to Improve Clinical Trial Retention |
Xtalks — The Life Science Community™, Online webinar | ||||||||||||||
| 2026-11-03 Others: Sterile drug product fill-finish is where years of development either pay off or unravel. Partnering with a CDMO that has isolator lines does not guarantee success. The difference lies in the depth of Fill-Finish Success: From Isolator Qualification to GMP Production |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-03 Others: Lyophilization has become an important development and commercialization strategy for modern parenteral products, including biologics, antibody-drug conjugates, mRNA-lipid nanoparticles, viral vectors Lyophilization by Design: Improve Stability and Accelerate Scale-Up (Broadcast 1) |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-04 Microbiology / Virology: Clinical trial feasibility has long been constrained by the same fundamental problem: the data used to estimate patient availability rarely reflects the patients who will actually enroll. Site surveys Feasibility Without Guesswork: Unlocking Genomic and Real-World Data for Faster Study Execution |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-04 Others: Bispecific antibodies are among the most promising and most demanding modalities in biologics today. Their dual-targeting architecture introduces molecular complexity that monoclonal antibody platform An Integrated Approach to De-Risking Bispecific Antibody Development |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-05 Others: Life sciences organizations have more data than ever, yet many of the sources used to guide Commercial and Medical Affairs' strategy reveal market change weeks or months after it occurs. This webinar Detect Clinician Activity Shifts Earlier to Improve Market Readiness |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-05 Microbiology / Virology: In vivo CAR-T therapy requires durable, yet transient CAR expression coupled with efficient, T cell-specific delivery. This webinar will focus on how innovations in RNA design and next-generation lipi Advances in mRNA & LNP technology for in vivo CAR-T therapy |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-05 Others: Biological processes are shaped by changes across multiple molecular layers, including RNA and proteins, with no single layer telling the whole story. Integrating complementary modalities can provide Maximize Tissue Insights with Spatial Transcriptomics and Proteomics |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-06 Others: Paediatric and adolescent obesity trials are now an established part of drug development, but major evidence gaps remain when translating findings across age groups. Regulatory architecture, including Improve Paediatric Obesity Trials with Evidence-Based Design |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-09 Others: Liquid biopsy has made it possible to detect and characterize cancer from a blood sample, with much of the field focused on circulating tumor DNA (ctDNA). Detection in early-stage disease remains chal Beyond ctDNA: EVPs and the Future of Early Cancer Detection |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-09 Microbiology / Virology: The diabetes clinical trial landscape is evolving rapidly. As type 1 diabetes programs expand and innovative therapies, including cell and gene therapies, move into clinical development, sponsors face Advancing Diabetes Clinical Trials Through Integrated Technology and Operational Oversight |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-10 Others: Early-phase neuroscience trials have traditionally focused primarily on establishing safety and tolerability. From Alzheimer's disease to psychiatry, early development strategies can also generate mea Lessons Learned in Neuroscience Drug Development: How Biomarker-based, Evidence-driven Decisions Enable Successful Outcomes |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-11 Others: As the biologics landscape becomes increasingly complex and therapeutic modalities grow more sophisticated, potency assay strategies are evolving from regulatory requirements into powerful tools that Potency Assays for Modern Biologics: Expert Insights and Future Trends |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-12 Microbiology / Virology: Cell and gene therapies (CGTs) present unique development challenges, from novel manufacturing processes and delivery methods to complex nonclinical programs and evolving regulatory expectations. For FDA Meetings: Engaging Regulators Throughout Cell and Gene Therapy Development |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-12 Others: Psychiatric drug development still leans on rating scales developed decades ago: subjective instruments that capture how a patient describes feeling but not what the brain is doing. In major depressiv Can Objective Brain Measures Improve MDD Trial Decisions? |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-12 Others: Enzyme replacement therapies have transformed the treatment landscape for many rare genetic and metabolic disorders by addressing enzyme deficiencies that drive disease progression. By supplying a fun Enzyme Therapy Manufacturing: Preserving Activity Through Production |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-16 Microbiology / Virology: Executing clinical trials in complex glomerular diseases require moving beyond traditional functional involvement. As treatment paradigms and regulatory expectations for surrogate endpoints evolve, in Navigating the Evolving Landscape of Glomerular Disease Clinical Trials |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-17 Others: As biopharmaceutical programs advance under increasingly compressed timelines, upstream development teams face pressure to deliver optimized, quality-targeted processes earlier. Early decisions still Accelerate Upstream Process Development Using Hybrid Modeling |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-17 Microbiology / Virology: Therapeutic antibodies are a rapidly growing class of drugs. Their application areas are not only limited to the standard immunoglobulin G (IgG) format but can also be extended to novel formats, inclu Platform Selection and Development Strategies for High-Performance Anti-Idiotype Antibody Development – in Just 9 Weeks |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-17 Others: Early-phase clinical trials operate under compressed timelines, complex protocols, narrow eligibility criteria and limited patient populations, making even small delays disproportionately costly. For Accelerate Biotech Patient Recruitment with Smarter Site Selection |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-18 Others: Successful biologics programs depend on making the right decisions at the right stage of development. Early choices in cell culture strategy, media and feed optimization, downstream recovery, analytic Reduce Biologics Development Risk Across the Product Life Cycle |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-19 Others: Artificial Intelligence (AI) is rapidly transforming biometrics functions across the clinical trial lifecycle, from protocol design and statistical analysis planning to programming, data standardizati AI Governance in Clinical Trial Biometrics: A Practical Framework for Small-Mid Size Organization |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| 2026-11-26 Others: Lyophilization has become an important development and commercialization strategy for modern parenteral products, including biologics, antibody-drug conjugates, mRNA-lipid nanoparticles, viral vectors Lyophilization by Design: Improve Stability and Accelerate Scale-Up (Broadcast 2) |
Xtalks — The Life Science Community™, Online webinar | |||||||||||||||
| December 2026 | 2026-12-15 Others: Decisions made early in the drug development process from preclinical through Phase IIa can disproportionately impact later development as costs increase with each phase. Timely information quantifyin Use PET and MRI Imaging Methods Early to Reduce Drug Development Risk |
Xtalks — The Life Science Community™, Online webinar | ||||||||||||||
| July 2027 | Boston, MA Gene Therapy: 4th Global Cell and Gene Therapy Summit 4th Global Cell and Gene Therapy Summit (CGT Summit 2027) |
United Scientific Group, Four Points by Sheraton Wakefield Boston Hotel & Conference Center | ||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||